Time to Buy Horizon Pharma PLC After Today’s Option Traders Bet?

 Time to Buy Horizon Pharma PLC After Today's Option Traders Bet?

In today’s session Horizon Pharma PLC (HZNP) registered an unusually high (403) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the January, 2017 call, expecting serious HZNP increase. With 403 contracts traded and 321664 open interest for the Jan, 17 contract, it seems this is a quite bullish bet. The option with symbol: HZNP170120C00024000 closed last at: $2.25 or 2.3% up. About 218,046 shares traded hands. Horizon Pharma PLC (NASDAQ:HZNP) has risen 8.08% since March 7, 2016 and is uptrending. It has outperformed by 0.49% the S&P500.

Analysts await Horizon Pharma PLC (NASDAQ:HZNP) to report earnings on November, 4. They expect $0.67 earnings per share, up 13.56% or $0.08 from last year’s $0.59 per share. HZNP’s profit will be $107.94 million for 7.16 P/E if the $0.67 EPS becomes a reality. After $0.42 actual earnings per share reported by Horizon Pharma PLC for the previous quarter, Wall Street now forecasts 59.52% EPS growth.

Horizon Pharma PLC (NASDAQ:HZNP) Ratings Coverage

Out of 9 analysts covering Horizon Pharma (NASDAQ:HZNP), 5 rate it a “Buy”, 0 “Sell”, while 4 “Hold”. This means 56% are positive. $40 is the highest target while $21 is the lowest. The $28.83 average target is 50.31% above today’s ($19.18) stock price. Horizon Pharma has been the topic of 18 analyst reports since September 9, 2015 according to StockzIntelligence Inc. The firm earned “Buy” rating on Tuesday, November 10 by Mizuho. The company was reinitiated on Wednesday, September 9 by JMP Securities. Morgan Stanley reinitiated the stock with “Underweight” rating in Thursday, December 3 report. The rating was initiated by Goldman Sachs on Monday, June 6 with “Buy”. The rating was initiated by Mizuho with “Buy” on Friday, October 9. The firm earned “Buy” rating on Monday, December 14 by Mizuho. Morgan Stanley upgraded Horizon Pharma PLC (NASDAQ:HZNP) on Monday, July 11 to “Equal-Weight” rating. The stock has “Neutral” rating given by Citigroup on Wednesday, January 6. The firm has “Buy” rating given on Tuesday, January 19 by Jefferies. The company was initiated on Thursday, December 17 by Goldman Sachs.

According to Zacks Investment Research, “Horizon Pharma plc is a specialty biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs. The company markets a portfolio of products in arthritis, inflammation and orphan diseases. The company’s U.S. marketed products are ACTIMMUNE® (interferon gamma-1b), DUEXIS® (ibuprofen/famotidine), PENNSAID® (diclofenac sodium topical solution) 2% w/w, RAYOS® (prednisone) delayed-release tablets and VIMOVO® (naproxen/esomeprazole magnesium). Horizon’s global headquarters are in Dublin, Ireland.”

Insitutional Activity: The institutional sentiment increased to 1.21 in Q2 2016. Its up 0.21, from 1 in 2016Q1. The ratio is positive, as 46 funds sold all Horizon Pharma PLC shares owned while 45 reduced positions. 38 funds bought stakes while 72 increased positions. They now own 135.34 million shares or 2.87% less from 139.33 million shares in 2016Q1.
Janus Mngmt accumulated 0.06% or 4.04 million shares. Millennium Management Limited Liability Company, a New York-based fund reported 150,675 shares. Tower Cap Ltd (Trc) owns 1,095 shares or 0% of their US portfolio. Aqr Cap Mgmt Ltd has 0% invested in the company for 86,846 shares. Blue Clay Cap Mngmt Llc holds 0.59% or 31,000 shares in its portfolio. Jw Asset Mgmt Ltd Liability Company owns 629,075 shares or 8.24% of their US portfolio. Balasa Dinverno And Foltz Ltd Liability Com has invested 0.21% of its portfolio in Horizon Pharma PLC (NASDAQ:HZNP). Swiss Bank holds 243,556 shares or 0.01% of its portfolio. Gilder Gagnon Howe & Co Ltd Liability Com holds 0% or 4,709 shares in its portfolio. Emerald Mutual Fund Advisers Tru reported 31,117 shares or 0.03% of all its holdings. Broadfin Ltd Com last reported 6.86 million shares in the company. Point72 Asset Management Lp holds 0.04% of its portfolio in Horizon Pharma PLC (NASDAQ:HZNP) for 359,800 shares. Strs Ohio has invested 0% of its portfolio in Horizon Pharma PLC (NASDAQ:HZNP). Carroll Fincl Associate Inc owns 700 shares or 0% of their US portfolio. Discovery Cap Mgmt Ltd Ct accumulated 3.51 million shares or 1.33% of the stock.

Insider Transactions: Since June 15, 2016, the stock had 0 insider buys, and 2 sales for $500,280 net activity. SHERMAN JEFFREY W sold $58,000 worth of stock. $442,280 worth of Horizon Pharma PLC (NASDAQ:HZNP) was sold by Nohria Virinder.

Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, is a biopharmaceutical company. The company has a market cap of $3.09 billion. The Firm is focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products. It currently has negative earnings. It markets approximately nine medicines through its orphan, primary care and rheumatology business units.

HZNP Company Profile

Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, incorporated on December 20, 2011, is a biopharmaceutical company. The Firm is focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products. The Firm markets approximately nine medicines through its orphan, primary care and rheumatology business units. The Company’s segment focuses on the identification, development, acquisition and commercialization of differentiated and accessible medicines. The Company’s marketed medicines include ACTIMMUNE (interferon gamma-1b), BUPHENYL (sodium phenylbutyrate) Tablets and Powder, DUEXIS (ibuprofen/famotidine), KRYSTEXXA (pegloticase), MIGERGOT (ergotamine tartrate and caffeine suppositories), PENNSAID (diclofenac sodium topical solution) 2% w/w, or PENNSAID 2%, RAVICTI (glycerol phenylbutyrate) Oral Liquid, RAYOS (prednisone) delayed-release tablets and VIMOVO (naproxen/esomeprazole magnesium). The Firm also developed DUEXIS and RAYOS, known as LODOTRA.

More recent Horizon Pharma PLC (NASDAQ:HZNP) news were published by: Streetinsider.com which released: “Horizon Pharma plc (HZNP) to Acquire Raptor Pharmaceutical (RPTP) for $800M” on September 12, 2016. Also Moodys.com published the news titled: “Moody’s: Horizon’s Raptor acquisition credit negative” on September 12, 2016. Seekingalpha.com‘s news article titled: “Horizon Pharma: Another Core Plus Biotech Worth Buying” with publication date: September 28, 2016 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Related posts

Leave a Comment